US Bancorp DE Reduces Holdings in IQVIA Holdings Inc. $IQV

US Bancorp DE trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 10.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,574 shares of the medical research company’s stock after selling 3,538 shares during the period. US Bancorp DE’s holdings in IQVIA were worth $6,892,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Claret Asset Management Corp lifted its position in shares of IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares during the period. Versant Capital Management Inc lifted its position in IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after acquiring an additional 53 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. lifted its position in IQVIA by 3.3% during the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 58 shares during the period. Brookstone Capital Management lifted its position in IQVIA by 2.2% during the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after acquiring an additional 63 shares during the period. Finally, Private Advisor Group LLC lifted its position in IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Evercore reissued an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Morgan Stanley set a $240.00 price target on shares of IQVIA in a research report on Wednesday, February 11th. Citigroup lowered their price target on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Buy” and an average price target of $226.63.

IQVIA Stock Down 0.0%

NYSE:IQV opened at $157.73 on Monday. The firm has a market cap of $26.77 billion, a P/E ratio of 20.07, a P/E/G ratio of 1.57 and a beta of 1.18. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The firm has a 50-day simple moving average of $169.36 and a two-hundred day simple moving average of $201.53.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.5 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.